Vasomotor sympoms and bone loss are complications frequently induced by adjuvant treatment for breast cancer.Tibolone prevents both side-effects,but its effect on cancer recurrence is unknown. The aim ov this study was to show non-inferiority of tibolone to placebo regarding risk of recurrence in breast-cancer patients with climacteric complaints.